Gilles is an Associate at Forbion and joined the Forbion team in March 2023 as a Fellow. Since then, he has been involved across both Forbion's Ventures and Growth strategies and is currently board observer at Purespring Therapeutics, LoQus23, and an early stealth company.
Before joining Forbion, Gilles received his PhD in Oncology at the Erasmus Medical Center in Rotterdam. During his PhD he focused on the development of organoid-based preclinical models of liver cancer and published more than 10 papers in high impact journals such as Cancer Cell and Cell Stem Cell. Before his PhD, he gained experience in assessing life science-related companies as part of the equities research team in the life sciences department at Van Lanschot Kempen.
Gilles also holds a double degree (MSc and MPhil) in Biofabrication from the University of Utrecht and University of Wollongong (Australia), and a BSc from University College Utrecht.
Joining Forbion has been a truly rewarding experience. I am proud to be part of a highly collaborative team that leverages deep expertise, along with a strong network, to drive progress in the development of innovative therapies. Our collective commitment and shared drive to translate innovative ideas into meaningful healthcare advances serve as a strong foundation for our work, ultimately enabling us to deliver real benefits that improve patients’ lives.
Portfolio
Companies worked on by Gilles van Tienderen
